Proof of principle for epitope-focused vaccine design. Correia BE, Bates JT, Loomis RJ, Baneyx G, Carrico C, Jardine JG, Rupert P, Correnti C, Kalyuzhniy O, Vittal V, Connell MJ, Stevens E, Schroeter A, Chen M, Macpherson S, Serra AM, Adachi Y, Holmes MA, Li Y, Klevit RE, Graham BS, Wyatt RT, Baker D, Strong RK, Crowe JE, Johnson PR, Schief WR (2014) Nature 507: 201-6 Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Yu X, Tsibane T, McGraw PA, House FS, Keefer CJ, Hicar MD, Tumpey TM, Pappas C, Perrone LA, Martinez O, Stevens J, Wilson IA, Aguilar PV, Altschuler EL, Basler CF, Crowe JE (2008) Nature 455: 532-6 Serum neutralizing antibody response to the vacuolating cytotoxin of Helicobacter pylori. Cover TL, Cao P, Murthy UK, Sipple MS, Blaser MJ (1992) J Clin Invest 90: 913-8 Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design. Crowe JE (2017) Cell Host Microbe 22: 193-206 Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Julg B, Tartaglia LJ, Keele BF, Wagh K, Pegu A, Sok D, Abbink P, Schmidt SD, Wang K, Chen X, Joyce MG, Georgiev IS, Choe M, Kwong PD, Doria-Rose NA, Le K, Louder MK, Bailer RT, Moore PL, Korber B, Seaman MS, Abdool Karim SS, Morris L, Koup RA, Mascola JR, Burton DR, Barouch DH (2017) Sci Transl Med 9: A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Fibriansah G, Tan JL, Smith SA, de Alwis R, Ng TS, Kostyuchenko VA, Jadi RS, Kukkaro P, de Silva AM, Crowe JE, Lok SM (2015) Nat Commun 6: 6341 Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Ortiz GM, Wellons M, Brancato J, Vo HT, Zinn RL, Clarkson DE, Van Loon K, Bonhoeffer S, Miralles GD, Montefiori D, Bartlett JA, Nixon DF (2001) Proc Natl Acad Sci U S A 98: 13288-93 Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Messer WB, de Alwis R, Yount BL, Royal SR, Huynh JP, Smith SA, Crowe JE, Doranz BJ, Kahle KM, Pfaff JM, White LJ, Sariol CA, de Silva AM, Baric RS (2014) Proc Natl Acad Sci U S A 111: 1939-44 Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody. Shanker S, Czakó R, Sapparapu G, Alvarado G, Viskovska M, Sankaran B, Atmar RL, Crowe JE, Estes MK, Prasad BV (2016) Proc Natl Acad Sci U S A 113: E5830-E5837 Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity. Barbas CF, Crowe JE, Cababa D, Jones TM, Zebedee SL, Murphy BR, Chanock RM, Burton DR (1992) Proc Natl Acad Sci U S A 89: 10164-8 Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE, de Silva AM (2012) Proc Natl Acad Sci U S A 109: 7439-44 An unexpected counter-regulatory role of IL-10 in B-lymphocyte-mediated transplantation tolerance. Zhao G, Moore DJ, Lee KM, Kim JI, Duff PE, O'Connor MR, Hirohashi T, Lei J, Yang M, Markmann JF, Deng S (2010) Am J Transplant 10: 796-801 Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses. Agnihothram S, Gopal R, Yount BL, Donaldson EF, Menachery VD, Graham RL, Scobey TD, Gralinski LE, Denison MR, Zambon M, Baric RS (2014) J Infect Dis 209: 995-1006 Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo. Crowe JE, Gilmour PS, Murphy BR, Chanock RM, Duan L, Pomerantz RJ, Pilkington GR (1998) J Infect Dis 177: 1073-6 Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. Graham BS, McElrath MJ, Connor RI, Schwartz DH, Gorse GJ, Keefer MC, Mulligan MJ, Matthews TJ, Wolinsky SM, Montefiori DC, Vermund SH, Lambert JS, Corey L, Belshe RB, Dolin R, Wright PF, Korber BT, Wolff MC, Fast PE (1998) J Infect Dis 177: 310-9 Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. Smith SA, de Alwis R, Kose N, Durbin AP, Whitehead SS, de Silva AM, Crowe JE (2013) J Infect Dis 207: 1898-908 Reversion of somatic mutations of the respiratory syncytial virus-specific human monoclonal antibody Fab19 reveal a direct relationship between association rate and neutralizing potency. Bates JT, Keefer CJ, Utley TJ, Correia BE, Schief WR, Crowe JE (2013) J Immunol 190: 3732-9 Intracellular neutralization of a virus using a cell-penetrating molecular transporter. Sapparapu G, Sims AL, Aiyegbo MS, Shaikh FY, Harth EM, Crowe JE (2014) Nanomedicine (Lond) 9: 1613-24 Antibody-functionalized peptidic membranes for neutralization of allogeneic skin antigen-presenting cells. Wen Y, Liu W, Bagia C, Zhang S, Bai M, Janjic JM, Giannoukakis N, Gawalt ES, Meng WS (2014) Acta Biomater 10: 4759-4767 Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. Krause JC, Tumpey TM, Huffman CJ, McGraw PA, Pearce MB, Tsibane T, Hai R, Basler CF, Crowe JE (2010) J Virol 84: 3127-30 Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones. Smith SA, de Alwis AR, Kose N, Jadi RS, de Silva AM, Crowe JE (2014) J Virol 88: 12233-41 A monoclonal antibody specific for reovirus outer-capsid protein sigma3 inhibits sigma1-mediated hemagglutination by steric hindrance. Nason EL, Wetzel JD, Mukherjee SK, Barton ES, Prasad BV, Dermody TS (2001) J Virol 75: 6625-34 Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity. Chazal N, Singer G, Aiken C, Hammarskjöld ML, Rekosh D (2001) J Virol 75: 4014-8 Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine. Benhnia MR, Maybeno M, Blum D, Aguilar-Sino R, Matho M, Meng X, Head S, Felgner PL, Zajonc DM, Koriazova L, Kato S, Burton DR, Xiang Y, Crowe JE, Peters B, Crotty S (2013) J Virol 87: 1569-85 Structural Insights into Reovirus σ1 Interactions with Two Neutralizing Antibodies. Dietrich MH, Ogden KM, Katen SP, Reiss K, Sutherland DM, Carnahan RH, Goff M, Cooper T, Dermody TS, Stehle T (2017) J Virol 91: Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1. Messer WB, Yount BL, Royal SR, de Alwis R, Widman DG, Smith SA, Crowe JE, Pfaff JM, Kahle KM, Doranz BJ, Ibarra KD, Harris E, de Silva AM, Baric RS (2016) J Virol 90: 5090-5097 Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding. Longo NS, Sutton MS, Shiakolas AR, Guenaga J, Jarosinski MC, Georgiev IS, McKee K, Bailer RT, Louder MK, O'Dell S, Connors M, Wyatt RT, Mascola JR, Doria-Rose NA (2016) J Virol 90: 10574-10586 The cotton rat (Sigmodon hispidus) is a permissive small animal model of human metapneumovirus infection, pathogenesis, and protective immunity. Williams JV, Tollefson SJ, Johnson JE, Crowe JE (2005) J Virol 79: 10944-51 A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo. Williams JV, Chen Z, Cseke G, Wright DW, Keefer CJ, Tollefson SJ, Hessell A, Podsiad A, Shepherd BE, Sanna PP, Burton DR, Crowe JE, Williamson RA (2007) J Virol 81: 8315-24 An alphavirus replicon-based human metapneumovirus vaccine is immunogenic and protective in mice and cotton rats. Mok H, Tollefson SJ, Podsiad AB, Shepherd BE, Polosukhin VV, Johnston RE, Williams JV, Crowe JE (2008) J Virol 82: 11410-8 Structure-function characterization of three human antibodies targeting the vaccinia virus adhesion molecule D8. Matho MH, Schlossman A, Gilchuk IM, Miller G, Mikulski Z, Hupfer M, Wang J, Bitra A, Meng X, Xiang Y, Kaever T, Doukov T, Ley K, Crotty S, Peters B, Hsieh-Wilson LC, Crowe JE, Zajonc DM (2018) J Biol Chem 293: 390-401 Functional analysis of neutralizing antibodies against Clostridium perfringens epsilon-toxin. McClain MS, Cover TL (2007) Infect Immun 75: 1785-93 Antigenic diversity among Helicobacter pylori vacuolating toxins. Vinion-Dubiel AD, McClain MS, Cao P, Mernaugh RL, Cover TL (2001) Infect Immun 69: 4329-36 Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Mohan VP, Scanga CA, Yu K, Scott HM, Tanaka KE, Tsang E, Tsai MM, Flynn JL, Chan J (2001) Infect Immun 69: 1847-55 Human rotavirus VP6-specific antibodies mediate intracellular neutralization by binding to a quaternary structure in the transcriptional pore. Aiyegbo MS, Sapparapu G, Spiller BW, Eli IM, Williams DR, Kim R, Lee DE, Liu T, Li S, Woods VL, Nannemann DP, Meiler J, Stewart PL, Crowe JE (2013) PLoS One 8: e61101 Association of VH4-59 Antibody Variable Gene Usage with Recognition of an Immunodominant Epitope on the HIV-1 Gag Protein. Chukwuma VU, Hicar MD, Chen X, Nicholas KJ, Joyner A, Kalams SA, Landucci G, Forthal DN, Spearman PW, Crowe JE (2015) PLoS One 10: e0133509 Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth. Chukwuma VU, Kose N, Sather DN, Sapparapu G, Falk R, King H, Singh V, Lampley R, Malherbe DC, Ditto NT, Sullivan JT, Barnes T, Doranz BJ, Labranche CC, Montefiori DC, Kalams SA, Haigwood NL, Crowe JE (2018) PLoS One 13: e0209437 Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates. Bates JT, Pickens JA, Schuster JE, Johnson M, Tollefson SJ, Williams JV, Davis NL, Johnston RE, Schultz-Darken N, Slaughter JC, Smith-House F, Crowe JE (2016) Vaccine 34: 950-6 Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Crowe JE, Bui PT, Siber GR, Elkins WR, Chanock RM, Murphy BR (1995) Vaccine 13: 847-55 Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B. Zhan X, Hurwitz JL, Krishnamurthy S, Takimoto T, Boyd K, Scroggs RA, Surman S, Portner A, Slobod KS (2007) Vaccine 25: 8782-93
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.